Related Experiment Video

Updated: Apr 13, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia

Xia Jiang1, Cheryl Zi Hui Lim1, Zhimei Li1

  • 1Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, 138672, Singapore.

Plos One
|May 1, 2015
PubMed

Insights

A novel epigenetic drug, D9, effectively targets acute myeloid leukemia (AML) by depleting leukemia stem cells. This less toxic 3-Deazaneplanocin A analog shows promise for AML therapy.

Area of Science:

  • Oncology
  • Epigenetics
  • Cancer Therapeutics

Background:

  • Aberrant epigenetic modifications are key drivers in human cancers.
  • Epigenetic therapies targeting DNA methylation and histone deacetylation show clinical promise.
  • Targeting histone methylation for cancer therapy is an emerging field.

Purpose of the Study:

  • To develop and evaluate a less toxic analog of the histone methylation inhibitor 3-Deazaneplanocin A (DZNep) for acute myeloid leukemia (AML).
  • To investigate the efficacy of the novel analog, D9, in AML models.
  • To identify molecular mechanisms and therapeutic potential of D9 in AML.

Main Methods:

  • In vitro and in vivo studies using AML cell lines and patient-derived samples.
  • Gene expression analysis to identify D9-responsive genes and pathways.
  • Assessment of D9's effect on leukemia stem cells (LSCs) and chemotherapy-induced LSC enrichment.

Main Results:

  • The DZNep analog, D9, demonstrated efficacy in AML cell lines and patient samples.
  • D9 treatment led to the identification of genes associated with sensitivity and implicated in oncogenic signaling.
  • D9 effectively depleted leukemia stem cells and reduced AML cell survival, even after chemotherapy.

Conclusions:

  • D9 is a potent epigenetic compound with significant anti-AML activity.
  • D9 exhibits reduced toxicity compared to DZNep.
  • D9 shows potential as a novel therapeutic agent for acute myeloid leukemia by targeting leukemia stem cells.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.9K
Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine11:04

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine

Published on: June 13, 2022

3.6K

Related Concept Videos

Aryldiazonium Salts to Azo Dyes: Diazo Coupling01:11

Aryldiazonium Salts to Azo Dyes: Diazo Coupling

The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the para...
4.2K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Diazonium Group Substitution: –OH and –H01:19

Diazonium Group Substitution: –OH and –H

Nitrous acid, a weak acid, is prepared in situ via the reaction of sodium nitrite with a strong acid under cold conditions. This nitrous acid prepared in situ reacts with primary arylamines to form arenediazonium salts. Such reactions are known as diazotization reactions. As shown in Figure 1, the formation of arenediazonium salts begins with the decomposition of nitrous acid in an acidic solution to give nitrosonium ions.
3.5K
1° Amines to Diazonium or Aryldiazonium Salts: Diazotization with NaNO2 Mechanism01:37

1° Amines to Diazonium or Aryldiazonium Salts: Diazotization with NaNO2 Mechanism

Nitrous acid is a relatively weak and unstable acid prepared in situ by the reaction of sodium nitrite and cold, dilute hydrochloric acid. In an acidic solution, the nitrous acid undergoes protonation when it loses water to form a nitrosonium ion—an electrophile. Nitrous acid reacts with primary amines to give diazonium salts. The reaction is called diazotization of primary amines.
5.4K
Carboxylic Acids to Methylesters: Alkylation using Diazomethane01:33

Carboxylic Acids to Methylesters: Alkylation using Diazomethane

Carboxylic acids react with diazomethane in an ether solvent via alkylation at the carboxylate oxygen atom to give methyl esters of the corresponding acid with excellent yields.
3.3K